Back to Search Start Over

The role of ibrutinib in COVID-19 hyperinflammation: A case report

Authors :
Suzanne Maynard
Jose Ros-Soto
Aris Chaidos
Andrew Innes
Krushika Paleja
Eitan Mirvis
Noora Buti
Harriet Sharp
Renuka Palanicawandar
Dragana Milojkovic
Source :
International Journal of Infectious Diseases, Vol 105, Iss , Pp 274-276 (2021)
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

Immune modulation in COVID-19 is emerging as an important therapeutic strategy as increasing evidence suggests that inflammatory pathways are implicated in lung damage. Bruton tyrosine kinase inhibitors (BTKi), such as ibrutinib, are commonly used to treat indolent B-cell neoplasms and chronic graft-versus-host disease (GvHD). Given their potential to suppress pulmonary inflammatory cytokines and lessen acute lung injury, this could be applicable in the context of hospitalised COVID-19 patients. We describe an 81 year-old male receiving ibrutinib for Waldenstrom macroglobulinaemia (WM) who was hospitalised with COVID-19. On stopping the BTKi due to concerns of additional immunosuppression, he required non-invasive ventilation (NIV) in the intensive care unit (ICU) and demonstrated prompt clinical recovery when ibrutinib was reinstated. Continuing ibrutinib in patients with COVID-19 may be advantageous given its immunomodulatory properties and withdrawal of ibrutinib therapy may be detrimental. Further evidence is required to explore the potential therapeutic impact of BTKis and other immunomodulatory agents on the clinical course of COVID-19 as is currently being carried out in a number of clinical trials.

Details

Language :
English
ISSN :
12019712
Volume :
105
Issue :
274-276
Database :
Directory of Open Access Journals
Journal :
International Journal of Infectious Diseases
Publication Type :
Academic Journal
Accession number :
edsdoj.85d83e5aadde42838aab0d9702e47654
Document Type :
article
Full Text :
https://doi.org/10.1016/j.ijid.2021.02.056